PAVmed (Nasdaq:PAVM) announced today that it successfully completed the first human implants of its PortIO intraosseous infusion system.
New York-based PAVmed designed its PortIO system with an implantable intraosseous vascular access device and insertion kit. Instead of a catheter located in a vein, the system has a short extension from the device inserted by a physician into a bone, leaving the device to reside completely beneath the skin.
Get the full story at our sister site, Drug Delivery Business News.